Monte Rosa Therapeutics (GLUE) Research & Development (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Research & Development of $9.6 million for Q1 2026, up 137.35% year-over-year from $4.0 million in Q1 2025, and down 77.16% quarter-over-quarter from $42.0 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Research & Development (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 137.35% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $93.9 million (up 140.68% YoY), while the FY2025 annual figure was $141.5 million, up 880.46% from the prior year.
- Research & Development for Q1 2026 stood at $9.6 million, down from $42.0 million in the prior quarter.
- The five-year high for Research & Development was $42.0 million in Q4 2025, with the low at -$37.7 million in Q4 2023.
- The 5-year median for Research & Development is $21.3 million (2022), against an average of $17.1 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development slumped 251.73% in 2023, then soared 982.21% in 2025.
- Monte Rosa Therapeutics' Research & Development stood at $24.9 million in 2022, then plunged by 251.73% to -$37.7 million in 2023, then jumped by 110.28% to $3.9 million in 2024, then jumped by 982.21% to $42.0 million in 2025, then slumped by 77.16% to $9.6 million in 2026.
- Business Quant data shows GLUE's Research & Development at $9.6 million in Q1 2026, $42.0 million in Q4 2025, and $36.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 47.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.96 Mn |
| Mar 31, 2026 | 9.59 Mn |
| Dec 31, 2025 | 41.98 Mn |
| Sep 30, 2025 | 36.68 Mn |
| Jun 30, 2025 | 5.70 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 27.62 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 27.03 Mn |
| Dec 31, 2023 | -37.73 Mn |
| Sep 30, 2023 | 28.31 Mn |
| Jun 30, 2023 | 29.08 Mn |
| Mar 31, 2023 | 26.76 Mn |
| Dec 31, 2022 | 24.87 Mn |
| Sep 30, 2022 | 21.34 Mn |
| Jun 30, 2022 | 20.94 Mn |
| Mar 31, 2022 | 17.92 Mn |
| Dec 31, 2021 | 18.13 Mn |
| Sep 30, 2021 | 15.12 Mn |